JP2007517010A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517010A5
JP2007517010A5 JP2006546340A JP2006546340A JP2007517010A5 JP 2007517010 A5 JP2007517010 A5 JP 2007517010A5 JP 2006546340 A JP2006546340 A JP 2006546340A JP 2006546340 A JP2006546340 A JP 2006546340A JP 2007517010 A5 JP2007517010 A5 JP 2007517010A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006546340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517010A (ja
JP4958560B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2004/050046 external-priority patent/WO2005061489A1/en
Publication of JP2007517010A publication Critical patent/JP2007517010A/ja
Publication of JP2007517010A5 publication Critical patent/JP2007517010A5/ja
Application granted granted Critical
Publication of JP4958560B2 publication Critical patent/JP4958560B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006546340A 2003-12-24 2004-12-23 Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 Expired - Fee Related JP4958560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53237003P 2003-12-24 2003-12-24
US60/532,370 2003-12-24
PCT/GB2004/050046 WO2005061489A1 (en) 2003-12-24 2004-12-23 Heterocyclic derivatives as gpcr receptor agonists

Publications (3)

Publication Number Publication Date
JP2007517010A JP2007517010A (ja) 2007-06-28
JP2007517010A5 true JP2007517010A5 (https=) 2011-10-13
JP4958560B2 JP4958560B2 (ja) 2012-06-20

Family

ID=34710259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546340A Expired - Fee Related JP4958560B2 (ja) 2003-12-24 2004-12-23 Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体

Country Status (11)

Country Link
US (1) US8207147B2 (https=)
EP (1) EP1711491A1 (https=)
JP (1) JP4958560B2 (https=)
KR (1) KR101154830B1 (https=)
CN (1) CN1898235A (https=)
AU (1) AU2004303604B2 (https=)
BR (1) BRPI0418149A (https=)
CA (1) CA2549955A1 (https=)
NZ (1) NZ547965A (https=)
WO (1) WO2005061489A1 (https=)
ZA (1) ZA200605164B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724982B2 (en) 2014-10-10 2023-08-15 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7858800B2 (en) * 2004-06-30 2010-12-28 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP5065908B2 (ja) * 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
GB0428212D0 (en) * 2004-12-24 2005-01-26 Prosidion Ltd Compounds
EP1838311A1 (en) * 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP1910290A2 (en) 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2001851A2 (en) * 2006-03-28 2008-12-17 Novartis AG Amide derivatives and their application for the treament of g protein related diseases
KR20080109075A (ko) * 2006-04-06 2008-12-16 프로시디온 리미티드 헤테로사이클릭 ｇｐｃｒ 작용제
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
SG10201404220TA (en) 2006-04-11 2014-10-30 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
GB0610746D0 (en) * 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2112880A4 (en) 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
CA2672307A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
TWI414523B (zh) * 2006-12-28 2013-11-11 Metabolex Inc 用於治療糖尿病及代謝病症之雜環受體促效劑
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
EP2134704B1 (en) * 2007-03-08 2010-09-22 Irm Llc Compounds and compositions as modulators of gpr119 activity
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
RU2443699C2 (ru) * 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100130476A1 (en) * 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
WO2010084512A1 (en) 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
NZ597895A (en) 2009-08-05 2012-11-30 Daiichi Sankyo Co Ltd Amide derivative
CA2770405C (en) * 2009-08-05 2015-03-17 Daiichi Sankyo Company, Limited Sulfone derivative
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
AU2011256455A1 (en) 2010-05-17 2013-01-10 Array Biopharma Inc. Piperidinyl-substituted lactams as GPR119 modulators
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101563793B1 (ko) 2010-10-08 2015-10-27 카딜라 핼쓰캐어 리미티드 신규한 ｇｐｒ 119 작용물질
SG189320A1 (en) 2010-10-14 2013-05-31 Daiichi Sankyo Co Ltd Acylbenzene derivative
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102731492B (zh) * 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
CN102898400B (zh) * 2011-07-28 2015-04-29 北京韩美药品有限公司 Gpr119激动剂及其应用
BR112014001767A2 (pt) 2011-07-29 2017-02-14 Daiichi Sankyo Co Ltd composto, composição farmaccêutica, uso de um composto, e, método para o tratamento de uma doença
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2014133738A (ru) 2012-01-18 2016-03-10 Дайити Санкио Компани, Лимитед Замещенное производное фенилазола
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014016191A1 (en) 2012-07-24 2014-01-30 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
WO2019209962A1 (en) 2018-04-25 2019-10-31 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN113480522A (zh) * 2021-08-19 2021-10-08 守恒(厦门)医疗科技有限公司 新型苯基吡唑类衍生物及其在降血糖药物中的应用
CN113801110B (zh) * 2021-10-28 2023-07-18 河南省人民医院 1,2,4-噁二唑杂环化合物及其应用
WO2023122152A1 (en) * 2021-12-22 2023-06-29 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2025037036A1 (en) * 2023-08-17 2025-02-20 Sanofi Pyridyl imidazoles, their preparation and their therapeutic application

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
DE3244579A1 (de) * 1982-12-02 1984-06-07 Philips Patentverwaltung Gmbh, 2000 Hamburg Roentgengeraet mit einer in ihrer laengsrichtung verschiebbaren tischplatte
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH11236372A (ja) * 1997-05-30 1999-08-31 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造方法及び剤
DE19725450A1 (de) * 1997-06-16 1998-12-17 Hoechst Schering Agrevo Gmbh 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
DE19858193A1 (de) * 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxadiazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
JP2000143623A (ja) * 1998-08-28 2000-05-26 Dai Ichi Seiyaku Co Ltd 新規なスルホニル誘導体およびその塩
PT1123287E (pt) * 1998-10-23 2003-12-31 Dow Agrosciences Llc 1-(piridil substituido)-1,2,4-triazoles insecticidas
EP1816127A1 (en) * 1999-04-22 2007-08-08 H. Lundbeck A/S Triazine derivatives for use as selective npy (y5) antagonists
MXPA02001095A (es) 1999-07-30 2002-08-20 Vertex Pharma Derivados de amina ciclicos y aciclicos.
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE10039477A1 (de) * 2000-08-08 2002-02-21 Aventis Cropscience Gmbh Heterocyclylalkylazol-Derivate und ihre Verwendung als Schädlingsbekämpfungsmittel
US7074794B2 (en) * 2000-08-10 2006-07-11 Mitsubishi Pharma Corporation Proline derivatives and the use thereof as drugs
CN1853630A (zh) * 2001-02-21 2006-11-01 Nps制药公司 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
AU2003257637A1 (en) * 2002-08-23 2004-03-11 Dainippon Pharmaceutical Co., Ltd. Proline derivatives
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
BR0317230A (pt) * 2002-12-13 2005-10-25 Smithkline Beecham Corp Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto
US7361669B2 (en) * 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724982B2 (en) 2014-10-10 2023-08-15 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Similar Documents

Publication Publication Date Title
JP2007517010A5 (https=)
JP2008526724A5 (https=)
JP2006500348A5 (https=)
JP2007524696A5 (https=)
JP2007519735A5 (https=)
JP2006517572A5 (https=)
JP2009535362A5 (https=)
JP2007508359A5 (https=)
RU2014142598A (ru) Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
SK90297A3 (en) 1,4,5-tri-substituted imidazole compounds, producing method thereof, pharmaceutical composition containing them and their use
JP2019537594A5 (https=)
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2005510500A5 (https=)
JP2013517281A5 (https=)
JP2013514345A5 (https=)
JP2012530765A5 (https=)
JP2006528940A5 (https=)
JP2008513405A5 (https=)
JP2006524225A5 (https=)
JP2010539152A5 (https=)
CA2652834A1 (en) Substituted arylimidazolones and -triazolones and the use thereof
JP2014507464A5 (https=)
JP2013507366A5 (https=)
CA2656502A1 (fr) Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
JP2006522037A5 (https=)